Eloxx Pharmaceuticals, Inc

(NASDAQ:ELOX)

Latest On Eloxx Pharmaceuticals, Inc (ELOX):

Date/Time Type Description Signal Details
2023-05-15 23:20 ESTNewsEloxx Pharmaceuticals Non-GAAP EPS of -$2.88N/A
2023-04-03 20:35 ESTNewsEloxx Pharmaceuticals GAAP EPS of -$2.92N/A
2023-03-16 02:09 ESTNewsEloxx Pharmaceuticals (ELOX)Investor Presentation - SlideshowN/A
2022-12-01 10:05 ESTNewsEloxx Pharmaceuticals stock plummets on approval of reverse stock splitN/A
2022-11-11 09:18 ESTNewsEloxx Pharmaceuticals GAAP EPS of -$0.09N/A
2022-09-14 21:50 ESTNewsEloxx says lead asset failed in mid-stage cystic fibrosis trialN/A
2022-08-15 14:39 ESTNewsEloxx Pharmaceuticals GAAP EPS of -$0.12 in-lineN/A
2022-05-11 03:06 ESTNewsEloxx Pharmaceuticals GAAP EPS of $0.13 beats by $0.24N/A
2022-03-31 10:01 ESTNewsEloxx Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02N/A
2022-03-30 17:32 ESTNewsEloxx Pharma to target Alport syndrome with lead candidateN/A
2021-11-17 16:37 ESTNewsEloxx posts mid-stage data for cystic fibrosis therapyN/A
2021-11-17 16:37 ESTNewsEloxx phase 2 cystic fibrosis data fails to impress as shares fall 24%N/A
2021-09-10 00:14 ESTNewsFDA grants Fast Track designation to Eloxx Pharma's ELX-02 for cystic fibrosisN/A
2021-08-16 17:07 ESTNewsEloxx Pharmaceuticals EPS misses by $0.40N/A
2021-07-21 06:57 ESTNewsEloxx Pharmaceuticals gets $2.6M funding from Cystic Fibrosis FoundationN/A
2021-07-21 06:45 ESTNewsEloxx Pharma spikes after Roche Finance reveals stakeN/A
2021-07-21 06:20 ESTNewsEloxx provides enrollment and data timeline update for mid-stage cystic fibrosis trialN/A
2021-05-07 07:31 ESTNewsEloxx Pharmaceuticals EPS misses by $0.06N/A
2021-04-30 10:12 ESTNewsEloxx adds additional treatment arm to ongoing mid-stage cystic fibrosis studyN/A
2021-04-01 15:44 ESTNewsEloxx Pharmaceuticals acquires Zikani Therapeutics in all-stock dealN/A
2021-03-14 08:34 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 11:32 ESTEarnings EstimateAn EPS average of -$0.98 is estimated for the 2022 year.Sell
2021-03-12 11:32 ESTEarnings EstimateAn EPS average of -$0.18 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-12 03:03 ESTNewsEloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q4 2020 Results - Earnings Call TranscriptN/A
2021-01-13 13:03 ESTNewsEloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosisN/A
2020-12-17 16:53 ESTNewsEloxx Pharmaceuticals shares skyrocket, price remains volatileN/A
2020-12-06 17:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 19:51 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 11:52 ESTAnalyst RatingThe Analyst Target Price has decreased from $6.25 to $5.Neutral
2020-11-23 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-22 17:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 19:44 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 11:39 ESTAnalyst RatingThe Analyst Target Price has increased from $5.8 to $6.25.Buy
2020-11-10 11:45 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 11:49 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 15:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 07:30 ESTNewsEloxx Pharmaceuticals, Inc. (ELOX) CEO Greg Williams on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-06 07:50 ESTEarnings EstimateAn EPS average of -$0.21 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 07:13 ESTNewsEloxx Pharmaceuticals EPS beats by $0.03N/A
2020-11-02 17:09 ESTInsider TradeNeil S. Belloff has directly acquired 1,562 shares and currently holds 7,853 shares.Buy
2020-11-02 17:09 ESTInsider TradeGregory C. Williams has directly acquired 1,875 shares and currently holds 9,382 shares.Buy
2020-09-26 12:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:46 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 08:41 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 14:42 ESTNewsEloxx Pharma restarts mid-stage cystic fibrosis study in the U.S.N/A
2020-08-11 08:39 ESTFinancialsCompany financials have been released.Neutral
2020-08-08 15:55 ESTNewsEloxx Pharmaceuticals (ELOX) CEO Greg Williams on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-08 08:36 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 16:00 ESTNewsEloxx Pharmaceuticals EPS beats by $0.01N/A
2020-08-04 11:59 ESTNewsEloxx's ELX-02 an Orphan Drug in U.S. for cystic fibrosisN/A

About Eloxx Pharmaceuticals, Inc (ELOX):

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

ELOX Quotes by TradingView

See Advanced Chart

General

  • Name Eloxx Pharmaceuticals, Inc
  • Symbol ELOX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 25
  • Last Split Factor1:20
  • Last Split Date2017-12-20
  • Fiscal Year EndDecember
  • IPO Date2018-01-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.eloxxpharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 14.19
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.73
  • Next Year EPS Estimate -$0.88
  • Next Quarter EPS Estimate -$0.18
  • Return on Assets -43%
  • Return on Equity -149%
  • Earnings Per Share -$1.45
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 140.35 million
  • EBITDA -51542000
  • Analyst Target Price $5
  • Book Value Per Share $0.26
View More

Share Statistics

  • Shares Outstanding 40.21 million
  • Shares Float 27.05 million
  • % Held by Insiders 1116%
  • % Held by Institutions 52.32%
  • Shares Short 1.2 million
  • Shares Short Prior Month 1.16 million
  • Short Ratio 14.59
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 2.54
  • 52 Week High $4.94
  • 52 Week Low $1.44
  • 50 Day Moving Average 3.87
  • 200 Day Moving Average 3.34
View More

Dividends

  • Dividend Date 2017-12-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eloxx Pharmaceuticals, Inc (ELOX) Dividend Calendar:

ELOX's last dividend payment was made to shareholders on December 20, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eloxx Pharmaceuticals, Inc (ELOX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-12$N/A-$0.15-$0.2230.23%
2020-09-302020-11-06$N/A-$0.16-$0.1914.67%
2020-06-302020-08-06$N/A-$0.20-$0.213.38%
2020-03-312020-05-07$N/A-$0.35-$0.30-17.29%
2019-12-312020-03-06$N/A-$0.29-$0.3516.21%
2019-09-302019-11-06$N/A-$0.32-$0.4324.81%
2019-06-302019-08-07$N/A-$0.40-$0.35-14.81%
2019-03-312019-05-09$N/A-$0.33-$0.4120.21%
2018-12-312019-03-08$N/A-$0.40-$0.34-16.82%
2018-09-302018-11-08$N/A-$0.32-$0.321.02%
2018-06-302018-08-07$N/A-$0.42-$0.22-87.67%
2018-03-312018-05-10$N/A-$0.31-$0.22-40.91%
2017-12-312018-03-16$N/A-$0.31-$0.21-48.62%
2017-06-302017-08-16$N/A-$1.62
2017-03-312017-05-22$N/A-$1.76
2016-12-312017-02-10$N/A-$0.78
2016-09-302016-10-13$N/A-$3.03
2016-03-312016-05-12$N/A-$0.33
2015-12-312016-02-16$37500-$1.82
2015-09-302015-11-17$37500-$1.77
2015-03-312015-05-15$37500-$7.51
2014-12-312015-02-11$N/A-$7.78
2014-09-302014-11-18$N/A-$17.31
2014-03-312014-05-13$N/A-$15.65
2013-12-312014-02-18$N/A-$29.21
2013-03-312013-05-21-$13.64
2012-12-312013-02-14-$22.12
2012-09-302012-11-08-$50.44
2012-06-302012-09-28-$37.54
2012-03-312012-05-14-$33.28
2011-12-312012-02-14-$40.95
2011-09-302011-11-15$N/A-$49.13
2011-06-302011-09-29-$85.14
2011-03-312011-05-16-$56.66
2010-12-312011-02-10-$53.32
2010-09-302010-11-16-$106.16
2010-06-302010-09-29-$855.00
2010-03-312010-05-18-$333.91
2009-12-312010-02-17-$129.80
2009-09-302009-11-17-$17.17
2009-06-302009-09-29-$160.00
2009-03-312009-05-04-$139.91
2008-12-312009-02-18-$174.38
2008-09-302008-11-17-$128.56
2008-06-302008-09-29-$99.73
2008-03-312008-05-16-$232.51
2007-09-302007-11-15-$43.73
2006-12-312006-12-31-$131.61
2006-09-302006-11-07-$91.72
2006-06-302006-06-30-$100.00
2006-03-312006-03-31-$92.77
2005-12-312005-12-31-$118.19
2005-09-302005-09-30-$116.00
2005-06-302005-06-30-$60.00
2005-03-312005-03-31-$98.27
2004-12-312004-12-31-$70.21
2004-09-302004-09-30-$80.27
2004-06-302004-06-30-$60.00
2004-03-312004-03-31-$63.48
2003-12-312003-12-31-$133.59
2003-09-302003-09-30-$235.77
2003-03-312003-03-31-$86.82
2002-12-312002-12-31-$94.68
2002-09-302002-09-30-$86.64
2002-03-312002-03-31-$91.73
2001-12-312001-12-31-$143.94
2001-09-302001-09-30-$127.35
2001-03-312001-03-31-$114.04
2000-12-312000-12-31-$128.90
2000-09-302000-09-30-$128.62
2000-03-312000-03-31-$262.33
1999-12-311999-12-31-$157.26
1999-09-301999-09-30-$163.01
1999-03-311999-03-31-$181.57

Eloxx Pharmaceuticals, Inc (ELOX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.28 million N/A N/A N/A 5.68 million
Income Before Tax -6.13 million N/A N/A -13.95 million -11.63 million
Selling General Administrative 2.5 million N/A N/A 5.22 million 5.81 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -6.13 million N/A N/A N/A -11.49 million
Operating Income -5.81 million N/A N/A -13.77 million -11.49 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -145000
Net Income From Continuing Operations -6.13 million N/A N/A N/A -11.63 million
Net Income Applicable to Common Shares -6.13 million -6.62 million -7.89 million -13.95 million -11.63 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 6.75 million 11.25 million N/A N/A N/A
Change to Liabilities N/A N/A N/A N/A N/A
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities -1.25 million -456000 N/A N/A N/A
Change to Operating Activities N/A N/A N/A N/A N/A
Change in Cash 245000 4.48 million N/A N/A N/A
Total Cash from Operating Activities -5.26 million -6.32 million N/A N/A N/A
Depreciation 143000 161000 N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 16.25 million N/A N/A 20.78 million 22.73 million
Total Stockholder Equity 10.23 million N/A N/A 26.26 million 36.21 million
Other Current Liabilities 389000 843000 N/A N/A 403000
Total Assets 26.48 million N/A N/A 47.04 million 58.95 million
Common Stock 404000 403000 403000 403000 402000
Other Current Assets 1.23 million 52000 N/A 43000 43000
Retained Earnings -171.6 million -165.47 million -158.85 million -150.97 million -137.02 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 30000 30000 110000 110000 113000
Cash 24.67 million N/A N/A 25.88 million 22.49 million
Total Current Liabilities 9.84 million 9.99 million N/A 11.08 million 11.81 million
Other Stockholder Equity -1.83 million N/A 13000 65000 18000
Property, Plant & Equipment 133000 700000 843000 1 million 1.13 million
Total Current Assets 25.89 million 32.21 million N/A 45.93 million 57.71 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 10.23 million 15.08 million 20.29 million 26.26 million 36.21 million
Short Term Investments N/A N/A N/A 18.08 million 33.78 million
Long Term Debt 6.38 million N/A N/A 9.39 million 10.5 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 4.21 million 638000 N/A 1.39 million 1.87 million

Eloxx Pharmaceuticals, Inc (ELOX) Chart:

Eloxx Pharmaceuticals, Inc (ELOX) News:

Below you will find a list of latest news for Eloxx Pharmaceuticals, Inc (ELOX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eloxx Pharmaceuticals, Inc (ELOX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ELOX Trades:

Date Shares Price
Jun 13, 2022 2:27 PM EST7$0.2649
Jun 13, 2022 2:27 PM EST100$0.26
Jun 13, 2022 2:27 PM EST300$0.26

Eloxx Pharmaceuticals, Inc (ELOX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920074199/0001104659-20-074199-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920003880/0001104659-20-003880-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920025486/0001104659-20-025486-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920029714/0001104659-20-029714-index.htm
2020-03-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1035354/000110465920030225/0001104659-20-030225-index.htm
2020-03-138-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920033093/0001104659-20-033093-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920038015/0001104659-20-038015-index.htm
2020-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1035354/000110465920041842/0001104659-20-041842-index.htm
2020-04-01DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1035354/000110465920041849/0001104659-20-041849-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920058095/0001104659-20-058095-index.htm
2020-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920065330/0001104659-20-065330-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920074199/0001104659-20-074199-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920089953/0001104659-20-089953-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920091159/0001104659-20-091159-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920093546/0001104659-20-093546-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1035354/000110465920121826/0001104659-20-121826-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1035354/000117891320000377/0001178913-20-000377-index.htm
2020-03-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1035354/000119312520072903/0001193125-20-072903-index.htm
2019-12-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588919001569/0001415889-19-001569-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000195/0001415889-20-000195-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000196/0001415889-20-000196-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000197/0001415889-20-000197-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000201/0001415889-20-000201-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000500/0001415889-20-000500-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000501/0001415889-20-000501-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000595/0001415889-20-000595-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000596/0001415889-20-000596-index.htm
2020-03-044/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000636/0001415889-20-000636-index.htm
2020-03-044/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000637/0001415889-20-000637-index.htm
2020-03-044/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000638/0001415889-20-000638-index.htm
2020-03-044/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000639/0001415889-20-000639-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920000755/0001415889-20-000755-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001104/0001415889-20-001104-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001105/0001415889-20-001105-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001298/0001415889-20-001298-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001299/0001415889-20-001299-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001300/0001415889-20-001300-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001301/0001415889-20-001301-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001302/0001415889-20-001302-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001304/0001415889-20-001304-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001305/0001415889-20-001305-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001306/0001415889-20-001306-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001337/0001415889-20-001337-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001980/0001415889-20-001980-index.htm
2020-07-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920001981/0001415889-20-001981-index.htm
2020-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920002520/0001415889-20-002520-index.htm
2020-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1035354/000141588920002521/0001415889-20-002521-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1035354/000156459019041002/0001564590-19-041002-index.htm
2020-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1035354/000156459020009148/0001564590-20-009148-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1035354/000156459020023543/0001564590-20-023543-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1035354/000156459020038092/0001564590-20-038092-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1035354/000156459020051711/0001564590-20-051711-index.htm

Eloxx Pharmaceuticals, Inc (ELOX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eloxx Pharmaceuticals, Inc (ELOX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1116%
Institutional Ownership: 5232%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-15GREGORY L WEAVERInsiderBuy3,750.0011,517.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000755/0001415889-20-000755-index.htm
2019-12-26Robert WardCHAIRMAN AND CEOBuy35,599.00206,552.00https://www.sec.gov/Archives/edgar/data/1035354/000141588919001569/0001415889-19-001569-index.htm
2020-02-29Robert WardInsiderBuy76,806.00267,552.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000595/0001415889-20-000595-index.htm
2020-04-30Neil S. BelloffCOO, GENERAL COUNSEL &CORP SECBuy1,562.005,646.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920001104/0001415889-20-001104-index.htm
2020-01-30David P. SnowCHIEF BUSINESS OFFICERBuy6,250.006,250.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000196/0001415889-20-000196-index.htm
2020-01-30Neil S. BelloffGENERAL COUNSEL/CORPORATE SECRBuy6,250.006,250.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000195/0001415889-20-000195-index.htm
2020-07-30Neil S. BelloffCOO, GENERAL COUNSEL &CORP SECBuy1,563.006,750.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920001981/0001415889-20-001981-index.htm
2020-04-30Gregory C. WilliamsCHIEF EXECUTIVE OFFICERBuy1,875.006,785.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920001105/0001415889-20-001105-index.htm
2020-01-30Gregory C. WilliamsCHIEF OPERATING OFFICERBuy7,500.007,500.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000197/0001415889-20-000197-index.htm
2020-10-30Neil S. BelloffCOO, GENERAL COUNSEL &CORP SECBuy1,562.007,853.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920002520/0001415889-20-002520-index.htm
2020-07-30Gregory C. WilliamsCHIEF EXECUTIVE OFFICERBuy1,875.008,083.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920001980/0001415889-20-001980-index.htm
2020-02-29David P. SnowInsiderBuy4,688.008,893.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000596/0001415889-20-000596-index.htm
2020-10-30Gregory C. WilliamsCHIEF EXECUTIVE OFFICERBuy1,875.009,382.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920002521/0001415889-20-002521-index.htm
2020-01-30GREGORY L WEAVERCHIEF FINANCIAL OFFICERBuy5,000.009,500.00https://www.sec.gov/Archives/edgar/data/1035354/000141588920000201/0001415889-20-000201-index.htm